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1. Introduction
X-linked recessive myotubular myopathy (XLMTM)
is a congenital myopathy characterized by severe
hypotonia and generalized muscle weakness after birth in
affected males1, 2). Polyhydraminos and weak fetal
movement are observed in prenatal onset. The
majority of patients died within the first few months of
the life by respiratory insufficiency. The characteristics
of muscle histopathology consist of small rounded
muscle cells, these resemble fetal myotubes3, 4). XLMTM
results from an arrest in the normal development of
muscle fibers by impaired maturation5).
MTM1 gene, the responsible gene for XLMTM,
was isolated by a positional cloning strategy from
proximal Xq28 region6). The MTM1 gene is composed
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Abstract
The purposes of this study are to establish the effective and efficient screening protocol
identifying the gene mutation, and to clarify the relationship between genotype and phenotype of X-
linked myotubular myopathy (XLMTM) using the molecular genetic method. Five male patients in
five families with XLMTM based on clinical features and muscle biopsy were analyzed according to
the screening protocol.
Three types of abnormal band were identified by SSCP and HD analysis using genomic DNA
from patients. In the direct sequence analysis, two frameshift mutations in exon 4 and 10 and one
nonsense mutation in exon 3 were found. Frameshift mutation in exon 10 was a novel mutation.
RT-PCR method was performed to the other patients who showed no abnormal bands by SSCP
and HD. In the direct sequence analysis, one missense mutation was found in exon 9. This mutation
was a novel mutation. The relationship between phenotype and genotype was not clarified.
The screening protocol employed in this study detected the three mutations in genomic DNA
and the one mutation in cDNA. The patient whom the mutation was not found was supposed to have
the mutation in non-coding region of MTM1 gene. Present protocol is considered to be suitable to
detect the mutations in XLMTM.
Key words: X-linked recessive myotubular myopathy, MTM1 gene, Mutation screening, 
Genetic analysis, RT-PCR method
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of 15 exons and 603 amino acids and encodes
myotubularin with a putative tyrosine phosphatase
domain. Tyrosine phosphatases have been shown to be
involved in transduction pathways controlling cell
growth and differentiation.
Almost patients with XLMTM are severe, but a
few patients survive for several years with medical
complications and may show spontaneous
improvement of the respiratory function after birth7).
The clinical feature of XLMTM patients tends to be
influenced by their genotype. Therefore, detecting the
gene mutation rapidly and accurately is very
important and provides valuable information for the
later management.
The purposes of this study are to establish the
effective and efficient screening protocol identifying
the gene mutation of XLMTM, and to clarify the
relationship between genotype and phenotype of
XLMTM using the molecular genetic method. This
study would contribute to the development of the
rehabilitation science.
2. Patients, materials and method (Fig. 1)
2. 1. Patients
Five male patients in five families with severe
phenotype of XLMTM were analyzed based on clinical
features and muscle biopsy (Fig. 2). Peripheral blood or
muscle tissue was obtained from patients and their
parents according to informed consent from those
parents.
2. 2. Genomic mutation screening
Genomic DNA of the patients and their parents
were extracted from peripheral blood lymphocytes or
muscle tissues using Sepa Gene kit (Sanko Jun-yaku).
Fifteen exons of MTM1 gene were amplified by
polymerase chain reaction (PCR). PCR amplification of
all exons was carried out using GeneAmp PCR System
9600 (Applied Biosystems)8). Two types of PCR
condition were designed to obtain the better PCR
products in the quality. For exon 3, 5, 7, 9-14, initial
Fig. 1.   Screening protocol of  X-linked myotubular myopathy
Genomic DNA 
PCR amplification for 15 exons in MTM1 gene
SSCP and HD analysis for detection of mutations
Sub-cloning  
RNA extraction
（＋） （－） 
Reverse transcript PCR
Sequencing by plasmid DNA or cDNA
Fig. 2. Pedigree of XLMTM families. Affected individuals are
indicated in black and the carrier indicated the circle with dot.
Deceased individuals are marked with slashes. Arrow
indicates propositus.
Family 1 Family 2
Family 4 Family 5
Family 3
Fig. 3. Principle of single-strand conformation polymorphism
analysis.
1) PCR for target DNA.  2) Denaturing the each PCR product
at 100 C゜  for 10 min. 3) Quickly on-ice for 10 min. 
4) Electrophoresis in MDETM gel at 20 mA for 6 hours in a cold
(4 C゜) room.  5) Silver staining.
PCR products of wild-type Affected PCR products
MDETM gel electrophoresis at 20 mA for 6 hours
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denaturation was at 94 °C for 1 min, followed by 30
cycles of 94 °C for 1 min, annealing at 60°C for 1 min,
and extension at 72°C for 1min. For residual exons (1,
2, 4, 6, 8, and 15), initial denaturation was at 95 °C for 2
min, and 28 cycles with denaturation at 95 °C for 15
sec, annealing at 60 °C for 15 sec, and extension at 72
°C for 45 sec. The final extension was at 72 °C for 7
min in either case.
2. 3. Screening
2. 3. 1. Single-strand conformation polymorphism
analysis (SSCP; Fig. 3)
One μl of PCR products added 15 μl of loading
buffer was denatured at 100 °C for 10 min and quickly
on ice for 10 min9, 10). The mixture loaded onto a gel in
1× TBE (Tris / Bolate / EDTA) buffer and
electrophoresis was performed at 20 mA for 6 hours at
4 °C in a cold room11).
The gel was silverstained in a room temperature.
The gel was immersed in gultaraldehyde / double
distilled water (DDW) (2:3) solution for 30 min initially.
After washing the gel, it was placed in 1N NaOH /
ammonia / 20 % silver nitrate / DDW (5:1:1:93) solution
for 15 min, and again rinsed in water. The gel was put
in 1 % citric acid / formaldehyde / DDW (10:1:200)
solution12).
2. 3. 2. Heteroduplex (HD) analysis (Fig. 4)
Five μl of PCR product of negative control and
patient were mixed respectively and the mixtures
were denatured at 95 °C for 3 min and annealed at 37
°C for 1 hour. One μl of loading buffer was added to 5
μl of the mixture and loaded onto a gel and
electrophoresis was performed at 800 V for 14 hours at
room temperature in 0.6×TBE buffer13). The gel was
stained in ethidium bromide for 15 min13, 14).
2. 4. Sub-cloning
Sub-cloning of mutant exon was performed using
Original TA cloning Kit (Invitrogen) and to obtain the
plasmid DNA, GFXTM Micro Plasmid Prep Kit
(Amersham phalmacia biotech.) was used. The
procedures were referred to manufacturer's
instructions.
2. 5. RNA isolation and reverse transcript-PCR
In XLMTM patients having no specific bands by
SSCP and HD analysis, reverse transcript-PCR (RT-
PCR) was performed to detect the splicing mutations in
exon/intron boundaries using their complementary
DNA (cDNA) synthesized from total RNA (tRNA).
tRNA was isolated from frozen muscle specimens
or peripheral blood lymphocytes on a guanidinium
thiocynate based extraction15). First-strand cDNA were
synthesized from tRNA using SUPERSCRIPT First-
Strand Synthesis System for RT-PCR kit (Invitrogen).
The full-length first-strand cDNA of MTM1 gene
obtained in the previous procedure were amplified
directly using PCR. The entire cDNA was divided into
six fragments (RTS1-6) and the primers sets were
designed referred to previous study (Table 1)16). PCR
was performed for 40 cycles with denaturation at 94 °C
for 1 min, annealing at 55 °C for 1 min, and extension
Fig. 4.   Principle of heteroduplex analysis. 1) PCR for target
DNA.  2) Mixed wild-type and affected PCR products. 
3) Denaturing the mixture at 95 C゜ for 3 min. 4) Annealing at
37 C゜ for 60 min.  5) Electrophoresis in MDETM gel at 800 V
for 14hours at room temperature.  6) Staining in ethidium
bromide.
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point mutation
heterpduplex band
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MDETM gel electrophoresis at 800 V for 14hours
Table 1． Primers set for RT-PCR in each fragment of 
MTM1 gene
Name Forward Reverse
RTS1
RTS2
RTS3
RTS4
RTS5
RTS6
5’-ATGGCTTCTGCATCAACTTC-3’
5’-GATTCTTCTCTAATACTTGATG-3’
5’-AGTGGAAGAATACAGGAGG-3’
5’-GCATATCATAACGCCGAAC-3’
5’-TGAAGGGTTCGAAATACTGG-3’
5’-CTGTTTCTTTATGGTCACTG-3’
5’-CTCGAGATCACACCCAGAG-3’
5’-CTGCCTCCTGTATTCTTCC-3’
5’-GAATAAACAATGTCCTTCAC-3’
5’-TCGAGATGCAAATTTATGTCC-3’
5’-GAAACAGTCCTTTCTGTAAC-3’
5’-GAAGTGAGTTTGCACATGG-3
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at 72 °C for 1min after denaturing at 94 °C for 2 min.
Final extension was 72 °C for 7 min. 0.4 μl of Taq
DNA Polymerase was added to the mixtures after
initial denaturation17). The PCR products were purified,
and subsequently direct sequence determination was
performed about all fragments.
2. 6. Direct sequencing determination
DNA sequencer SQ5500E (Hitachi Electronics
Engineering) was used for direct sequencing
Fig.5. SSCP analysis in exon 3 (family 1, A), exon 4 (family 2, B) and exon 10 (family 3, C) of MTM1 gene in controls and
XLMTM patients. A; Mutant bands are demonstrated in patient 1 (lane 3, arrowed) and his mother (lane 4). B; Mutant bands
are demonstrated in patient 2 (lane 3, arrowed) and his mother (lane 2). C; Mutant bands are demonstrated in patient 3 (lane 2,
arrowed) and his mother (lane 3).
Ａ Ｂ Ｃ
*1 *2 *3 *4 *5
*1. control (male)
*2. father of patient 1
*3. patient 1
*4. mother of patient 1
*5. control（female）
*1 *2 *3
*1. father of patient 2
*2. mother of patient 2
*3. patient 2
*1 *2 *3 *4
*1. father of patient 3
*2. patient 3
*3. mother of patient 3
*4. control
Fig.6. HD analysis in exon 3 (family 1, A), exon 4 (family 2, B) and exon 10 (family 3, C) of MTM1 gene in controls and XLMTM
patients. A; Mutant bands are demonstrated in patient 1 (lane 3, arrowed) and his mother (lane 4). B; Mutant bands are
demonstrated in patient 2 (lane 3, arrowed) and his mother (lane 2). C; Mutant bands are demonstrated in patient 3 (lane 2,
arrowed) and his mother (lane 3).
Ａ Ｂ Ｃ
*1 *2 *3 *4 *5
*1. aunt of patient 1
*2. mother of patient 1
*3. patient 1
*4. father of patient 1
*5, *6 control
*1 *2 *3 *4 *5
*1. control
*2. father of patient 2
*3. patient 2
*4. control
*5. mother of patient 2
*1 *2 *3
*1. father of patient 3
*2. patient 3
*3. mother of patient 3
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determination. The sequence reaction was performed
using the 500 ng of plasmid DNA obtained from sub
cloning (template DNA), Texas Red M13 forward
primer and Thermo Sequenase Core Seaquencing kit
(Hitachi measurement apparatus service).
Electrophoresis was carried out for 12 hours, checked
the fluorogram and determined base arrangement by
computer processing.
Sequence changes were identified by comparing
with the MTM1 cDNA sequence (Genbank, U46024) or
with the splice junction of MTM1 gene18).
3. Results
3. 1. Detection of mutations in screening tests
The results of the SSCP analysis was shown in
Fig. 5. In family 1 (Fig. 5, A), specific bands were
observed in exon 3 of MTM1 gene. In patient (lane 3),
specific band was observed (arrow). His mother (lane 4)
had both normal and specific bands. In family 2 (Fig. 5,
B), specific bands were observed in exon 4 of MTM1
gene. In patient 2 (lane 3), specific band was observed
(arrow). His mother (lane 2) had both normal and
specific bands.
In family 3 (Fig. 5, C), specific bands were
observed in exon 10 of MTM1 gene. In patient 3 (lane
2), specific band was observed (arrow). His mother (lane
3) had both normal and specific bands. In patient 4 and
5, the specific bands were not found in the SSCP.
The results of the HD analysis was shown in Fig.
6. In family 1 (Fig. 6, A), patient 1 (lane 3) had a mutant
homoduplex band (arrow). His aunt (lane 1) and mother
(lane 2) had a mutant (arrow) and a normal band. In
family 2 (Fig. 6, B), two abnormal bands were observed
in the patient (lane 3) and one band in his mother (lane
5). In family 3 (Fig. 6, C), patient 3 (lane 2) had a mutant
band, mother of patient 3 (lane 3) had a mutant and a
normal band.
In patient 4 and 5, specific bands were not
observed by the HD.
3. 2. Direct sequencing determination
The results of the direct sequence determinations
were shown in Fig. 7. In patient 1 (Fig. 7, A), one base
substitution (cDNA 109C-T), leading to an arginine to a
stop codon, was identified (nonsense mutation). In
patient 2 (Fig. 7, B), 4 bp deletion at cDNA 139-142
(AAAG) was identified, this mutation caused to shift
the reading frame and terminated translation at the
25th codon from deleted site (frameshift mutation). In
patient 3 (Fig. 7, C), 2 bp deletion of cDNA 1003-1004
Fig. 7.  Direct sequence analysis of MTM1 gene in genomic DNA in family 1(A-1; normal control in exon 3, A-2; patient 1), family
2 (B-1; normal control in exon 4, B-2; patient 2) and family 3(C-1; normal control in exon 10, C-2; patient 3) .
A-1 B-1 C-1
normal control normal control normal control
A-2 C→T substitution B-2 4 bp (AAAG) deletion C-2 2 bp (TC) deletion
patient 1 patient 2 patient 3
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(TC) or 1005-1006 (TC) was identified. This mutation
caused to shift the reading frame and terminated
translation at the 42nd codon from deleted site
(frameshift mutation). This mutation was not reported
in the previous studies (novel mutation).
In patient 4 and 5, the specific bands were not
observed by SSCP and HD. The direct sequence
determinations were performed about six fragments of
cDNA. In patient 4, mutations were not disclosed. In
patient 5 (Fig. 8, D), one base substitution (cDNA 688T-
A) was identified in RTS-3, corresponding to exon 9 in
genomic DNA. This mutation led from a tryptophan to
arginine (missense mutation). This mutation was not
reported in the previous studies (novel mutation).
4. Discussion
MTM1 gene was mapped to Xq28. The MTM1
gene is about 100 kb and consisted of 15 exons. It
encodes 603 amino acid protein6). Myotubularin, which
is encoded by MTM1 gene, is highly conserved
through the evolution. The function of myotubularin is
not well known, but was clarified containing the
consensus sequence of tyrosine phosphatases (PTP)
active site in exon 11 and SET interaction domain (SID)
in exon 12 and 13. This protein can dephosphorylate
phosphorylated serine and phosphorylated tyrosine. It
is considered to be a dual-specific phosphatase involved
in signal transduction pathways which are implicated
in muscle development19). The SET domain is
epigenetic regulatory machinery concerned with the
growth and differentiation of muscle20). As XLMTM
seems to be due to a defect in late myogenesis, the
regulation of the MTM1 gene transcription and/or
regulation of myotubularin activity might be an
essential step toward the complete maturation of
muscle fiber18). The results of these previous studies
Fig. 8.  Direct sequence analysis of MTM1 gene in cDNA in family 5 (D-1; normal control in RTS fragment 3, D-2; patient 5)
D-1
normal control
D-2 T→A substitution
patient 5
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indicate that the PTP and SID domains play important
roles in myotubularin. Truncated myotubularin might
be unstable and/or may display altered interaction
with other intracellular protein or subcellular
localization21).
In this study the mutations in MTM1 gene were
screened for all exons in five unrelated XLMTM
patients by the SSCP and the HD. The mutant band
was detected in the three among the five patients by
the SSCP and the HD but not in the two patients. In
the mutation screening, the SSCP and the HD have a
technical simplicity, a high sensitivity, validity and low
cost for the detection of sequence mutations11). The
level of sensitivity in SSCP and HD is 70 - 95 % and 80
- 90 %, respectively. The sensitivity is influenced by
some factors, e.g. the length of fragment, the type of
mutation and the matrix of running gel22). Rossetti et
al.13) reported that the combined efficiency of these two
methods was estimated to 100%. These screening
methods are thought to be effective techniques, but
present data suggests that the SSCP and the HD could
not detect mutations completely.
Next step, the RT-PCR was performed to two
patients who were found no mutation in genomic DNA
screening. The RT-PCR can be an alternative method
in order to avoid analysis of individual exons, but this
requires adequately stored cells8). The disadvantage of
this method is the need for ready access to a suitable
biological source from the patients. The mutation in
patient 5 was detected by the RT-PCR analysis. The
RT-PCR analysis must be performed in the cases that
mutations were not found in genomic DNA screening.
The screening protocol in the present study is
considered to be suitable and rational to detect the
mutations in coding region of MTM1 gene.
In the present study, the mutations were identified
in the four patients and the two out of those were
novel mutations (Table 2). Mutations have been
restricted to the coding region of MTM18, 23). Recently,
highly homologous gene, MTMR1, was identified lying
20 kb distal to MTM1 gene24). Copley et al.25) studied
that no mutations were found in MTMR1 gene in
fourteen XLMTM patients who had no mutations in
MTM1 gene. These suggest that MTMR1 is not
related to XLMTM. Kioschis et al.24) suggests some of
the mutations are located in non-coding regions (intron
or promoter region) of MTM1. It is suggested that the
mutations of one patient not identified in present study
will be located in non-coding region.
Laporte et al.26) reported the types and location of
mutations in XLMTM. One third of patients with a
missense mutation showed mild phenotype, most of the
patients with other types of mutation showed severe
phenotype.
Missense mutation is the most frequent in
XLMTM. 85 % of the missense mutations are located
from exon 8 to 12, includes PTP and SID domain. In
present study, missense mutation of the patient 5
(cDNA 688T-A) was observed in exon 9 of MTM1
gene, and he showed severe phenotype. 7 /13 of
missense mutations in exon 9 showed severe
phenotype, but the change of amino acid from
tryptophan to arginine was not reported in the
previous study. It is supposed that this amino acid
change may lead to severe phenotype.
The small deletion or insertion alters the reading
frame of sequence. Two small deletions were found in
present study. In patient 2, AGAA deletion at cDNA
141-144 was identified, and this mutation was observed
in ten patients with previously reported XLMTM
Table 2.  Clinical features and genotype
* Mutation was not identified, so the mutation origin was not clarified.
** Blood sample was not obtained from the patient's family.
Patients Age/Sex hypotonia respiration exon / intron
nucleotide
change
predicted protein
alteration
mutational
origin
clinical feature genotype
patient 1
patient 2
patient 3
patient 4
patient 5
1 year / M
6 month / M
5 year / M
1 month / M
1 year / M
severe
severe
severe
severe
severe
ventilator
ventilator
ventilator
ventilator
ventilator
exon 3
exon 4
exon 10
－
exon 9
C109T
139-142
del AAAG
1003-1004
del TC
－
T688A
unknown*
unknown**
frameshift
truncation
Arg 37 Stop
truncation
frameshift
truncation
missense
Trp230Arg
mother
heterozygote
mother, aunt
heterozygote
mother
heterozygote
－
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patients. Their phenotypes were all severe, and patient
2 showed also severe. In patient 3, TC deletion at
cDNA 1003-1004 (exon 10) was identified, and this
mutation was a novel mutation. His phenotype was
severe. These deletions in present study truncated the
myotubularin, and led to severe phenotype.
The nucleotide change from C to T at cDNA 109
in the present study was observed in five patients in
previous study. Their phenotypes were all severe.
Nonsense mutation truncated the myotubularin, and
led to severe phenotype.
In medical management of rehabilitation, initial-
data collection from the patient and family is the
important information for the decision making and
later treatment27, 28). The accurate data is required for
establishing the appropriate plan to the goal, and the
therapeutics on inadequate data may impose severe
burden on the patient and the family. In addition, it is
supposed to be difficult to perform some examinations
as an initial-data collection in the disease which is
severe and early onset. To specify the pathogenesis of
a disease will estimate the prognosis, and support to
design for the suitable program. In some hereditary
diseases, previous studies indicate that the genotype
and the phenotype are correlated. XLMTM is a lethal
disease that most of the patients decease in a year, but
some of the patients survive in long term. They show
spontaneous improvement of the respiratory function.
In present study, patient 2 survives with respirator
now and is 5 years old. He has received respiratory
physical therapy and aims at home care. These
findings suggest the importance of effective care in
neonatal period of XLMTM. To identify the genotype
become an important and a reliable initial-data, and
enable the early treatment to forestall the progress in
hereditary diseases. Genotype analysis may lead to
predict the prognosis in XLMTM. Genetic diagnosis
supports the total management of hereditary disease in
rehabilitation approach.
In genotype-phenotype correlation in present
study, no obvious correlations are obtained between
the type of mutation and the severity of the disease.
The mutations truncate the essential function of this
protein lead to the severe phenotype. Analysis of the
genotype is considered to be particularly important in
diagnosis of XLMTM. The results of this study should
contribute to raise the quality of life of the patients and
their family.
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要　　　旨
本研究は遺伝性筋疾患であるX-linked myotubular myopathy（XLMTM）における遺伝子解析にお
いて、遺伝子変異を検出する効果的かつ効率的なスクリーニング方法を規定すること、および本疾患の
表現型と遺伝子型の関連を明らかにすることを目的とした。対象は臨床症状および筋生検によって重症
のXLMTMと診断された５家系５名の男児とし、スクリーニングプロトコルにしたがって解析を行った。
その結果、ゲノムDNAを用いたSSCPおよびHD解析において５名の患者のうち、３名について泳動
変異を検出した。これらの直接塩基配列決定の結果、２名のフレームシフト変異（エクソン４および10）
と１名のナンセンス変異（エクソン３）が確認された。エクソン10におけるフレームシフト変異は こ
れまで報告例のない新しい変異であった。
ゲノムDNAを用いたスクリーニングで泳動変異が観察されなかった２名の患者に対してはRT－PCR
法を用いたcDNAの直接塩基配列決定を行った。その結果、１名のミスセンス変異（エクソン９）を同
定し、これまで報告例のない新しい変異であることを確認した。残り１名については変異が確認できな
かった。表現型と遺伝子型の関係については、すべての患者が重症例であったこと、症例数が少なかっ
たことから明らかにできなかった。
本研究ではゲノムDNAで３名、cDNAで１名の遺伝子変異を確認したが、変異を確認できなかった患
者は非翻訳領域に変異が存在する可能性が考えられた。これらの結果から、本研究で実施したスクリー
ニングプロトコルはXLMTMにおける遺伝子変異検出に対し十分適切であることが考えられる。
＜索引用語＞X染色体劣性遺伝ミオチューブラーミオパチー、MTM1遺伝子、遺伝子変異スクリーニン
グ、遺伝子解析、RT-PCR法
